GÖTEBORG, Sweden--()--Regulatory News:
The Extraordinary General Meeting of Vitrolife AB (publ)(STO:VITR) will take place on Monday September 24, 2012, at 3 p.m. in the company’s premises at Gustaf Werners gata 2 in Gothenburg. Notice of attendance at the Extraordinary General Meeting shall be given no later than Tuesday, September 18, 2012, at 12 noon.
Shareholders wishing to participate at the Extraordinary General Meeting shall notify the company by mail to Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden, Att: Anita Ahlqvist, by phone +46 31 721 80 83, by fax +46 31 721 80 99 or by e-mail firstname.lastname@example.org. Name/business name, personal identification number/ company registration number (or the equivalent), address, telephone number, number of shares, details of any advisors and where appropriate details of a representative or proxy must be stated in the notification. A proxy form in Swedish for shareholders wishing to be represented by proxy will be found on www.vitrolife.com.
Shareholders that have their shares registered in the name of a nominee must temporarily record their shares in the share register kept by Euroclear Sweden AB in their own names to be able to attend the General Meeting. Such registration must be carried out no later than Tuesday, September 18, 2012.
The following proposals will be amongst those presented at the Extraordinary General Meeting:
· Resolution on distribution of shares in Xvivo Perfusion AB
· Resolution on new issue
Attachment: Full notice
Gothenburg, August 31, 2012
VITROLIFE AB (publ)
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on August 31, at 12:00 noon.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.
Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
This information was brought to you by Cision http://www.cisionwire.com